Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?

In this retrospective analysis, RA and RARS/RARS-t patients receiving ICT had superior OS to non-ICT patients. These findings should be verified and other MDS subtypes examined in larger prospective analyses.